Anya Loncaric
Bausch Health Americas, Inc. · Bausch & Lomb Incorporated · B+L
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anya Loncaric as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05229510 · Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy VolunteersBausch Health Americas, Inc. · completed · Healthy · study director
- N/ANCT05075746 · Retrospective Chart Review of enVista Toric 0.9D Intraocular LensesBausch & Lomb Incorporated · completed · Corneal Astigmatism · study director
- Ph1NCT04551768 · Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19Bausch Health Americas, Inc. · completed · COVID19 · study director
- Ph1NCT04356677 · Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2Bausch Health Americas, Inc. · withdrawn · COVID19 · study director
- N/ANCT04224155 · Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract ExtractionBausch & Lomb Incorporated · completed · Cataract · study director
- Ph3NCT04214639 · Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph3NCT04214652 · Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- N/ANCT04192630 · A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50Bausch & Lomb Incorporated · completed · Cataract · study director
- N/ANCT04149587 · A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent RegimenBausch Health Americas, Inc. · completed · Psoriasis · study director
- Ph4NCT04140279 · A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionBausch & Lomb Incorporated · withdrawn · Ocular Hypertension · study director
- N/ANCT04111757 · A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic AstigmatismBausch & Lomb Incorporated · completed · Myopia, Myopic Astigmatism · study director
- Ph3NCT03664739 · Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph3NCT03664752 · Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph1NCT03653403 · Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control GelBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- N/ANCT03511638 · Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)Bausch & Lomb Incorporated · completed · Cataract · study director
- Ph2NCT03170388 · A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph3NCT03168321 · A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)Bausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph3NCT03168334 · A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)Bausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph1NCT03098953 · Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular InstallationsBausch & Lomb Incorporated · completed · Healthy · study director
- Ph3NCT03058783 · Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult SubjectsBausch Health Americas, Inc. · completed · Atopic Dermatitis · study director
- Ph2NCT03003247 · Efficacy and Safety of IDP-120 Gel in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph2NCT02938494 · Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne VulgarisBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph1NCT02849860 · Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne VulgarisBausch Health Americas, Inc. · completed · Acne · study director
- Ph1NCT02850003 · Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 GelBausch Health Americas, Inc. · completed · Acne · study director
- Ph1NCT02849873 · Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac CreamBausch Health Americas, Inc. · completed · Acne · study director
- Ph4NCT02767947 · Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea CorporisBausch Health Americas, Inc. · completed · Tinea Corporis · study director
- Ph4NCT02767271 · Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea CrurisBausch Health Americas, Inc. · completed · Tinea Pedis, Tinea Cruris · study director
- Ph2NCT02537483 · A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne VulgarisValeant Pharmaceuticals · unknown · Acne Vulgaris · study director
- Ph3NCT02535871 · A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisValeant Pharmaceuticals · unknown · Acne Vulgaris · study director
- Ph2NCT02525822 · Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne VulgarisValeant Pharmaceuticals · unknown · Acne Vulgaris · study director
- Ph3NCT02491060 · A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisValeant Pharmaceuticals · unknown · Acne Vulgaris · study director
- Ph4NCT02394340 · Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea CrurisBausch & Lomb Incorporated · completed · Tinea Pedis, Tinea Cruris · study director
- N/ANCT02394379 · Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOLBausch & Lomb Incorporated · completed · Cataract · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:38 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.J Drugs Dermatol · 20207 citationsRCR 0.9
- Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.J Drugs Dermatol · 20203 citationsRCR 0.3